고효능 원료의약품 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

High Potency Active Pharmaceutical Ingredients Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 고효능 원료의약품(HPAPI) 세계 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 촉진요인, 동향, 기회 및 과제를 포함한 주요 시장 역학을 철저히 평가하고 시장 구조에 대한 자세한 인사이트를 제공합니다.

주요 인사이트

• HPAPI 시장 규모(2024년) : 258억 달러
• 예상 시장 가치(2033년) : 651억 달러
• 세계 시장 성장률(2024-2033년 CAGR) : 10.9%

HPAPI 시장 : 조사 범위

고효능 원료의약품(HPAPI)은 저용량으로 높은 효능이 요구되는 의약품의 제형에 사용되는 중요한 성분입니다. HPAPI 시장은 제약회사, 연구기관, 위탁생산업체(CMO)를 대상으로 합성 HPAPI, 생명공학 HPAPI 및 기타 다양한 HPAPI를 포함한 다양한 성분을 제공하고 있으며, 종양학, 호르몬 요법 및 기타 다양한 치료 분야에서 일반적으로 사용되고 있습니다.

시장 성장 촉진요인은 만성 질환의 확산, 의약품 개발 기술의 발전, 표적 치료에 대한 수요 증가입니다. 효능 향상, 부작용 감소, 복잡한 병태생리를 치료할 수 있는 능력은 HPAPI의 채택을 촉진하는 주요 이점입니다.

시장 촉진요인:

세계 HPAPI 시장은 강력하고 효과적인 약물 개발이 필요한 암 및 기타 만성 질환의 발병률 증가와 같은 몇 가지 주요 요인에 의해 주도되고 있습니다. 표적 치료와 맞춤 치료로의 전환은 시장 확대를 더욱 촉진할 것입니다. 새로운 약물전달 시스템 및 연속 생산 공정 개발과 같은 기술 발전은 HPAPI의 생산 및 효능을 향상시켜 시장 성장을 촉진할 것입니다.

또한, 제약기업의 연구개발 투자 증가, 생물학적 제제 및 바이오시밀러의 부상도 HPAPI 수요 확대에 기여하고 있으며, CMO의 확대와 전문 시설에 대한 HPAPI 생산 아웃소싱도 시장 발전에 큰 역할을 하고 있습니다.

시장 억제요인:

유망한 성장 전망에도 불구하고 HPAPI 시장은 엄격한 규제 요건, 높은 제조 비용, 고활성 화합물 취급에 따른 안전 우려와 관련된 문제에 직면해 있으며, HPAPI 제조에 대한 규제 준수에는 작업자 안전 및 환경 보호를 위한 엄격한 기준이 포함되어 있어 제조 업체에게 운영 및 재정적 부담을 줄 수 있습니다.

또한, HPAPI 제조에 필요한 특수 시설 및 장비의 필요성을 포함하여 HPAPI 제조의 높은 비용은 특히 중소기업(SME)의 시장 침투를 가로막는 장애물이 되고 있습니다. 이러한 규제 및 경제적 장벽을 극복하기 위해서는 업계 이해관계자와 규제 기관이 협력하여 승인 프로세스를 간소화하고 비용 효율적인 제조 솔루션을 촉진해야 합니다.

시장 기회:

HPAPI 시장은 기술 혁신, 인구 동향, 진화하는 의료 서비스 제공 모델로 인해 큰 성장 기회를 맞이하고 있습니다. 연속 흐름 처리 및 고농도 봉쇄 시스템과 같은 첨단 제조 기술의 통합은 생산 효율성과 안전성을 향상시킵니다.

또한 자가면역질환, 호르몬 장애, 심혈관계 질환 등 HPAPI의 용도가 종양학 외에도 확대되면서 시장 범위가 넓어지고 기술 혁신이 촉진되고 있습니다. 전략적 파트너십, R&D 투자, 새로운 HPAPI 화합물 도입은 새로운 기회를 활용하고 역동적인 HPAPI 환경에서 시장 리더십을 유지하는 데 필수적입니다.

본 보고서에서 다루는 주요 질문들

• HPAPI 시장의 성장을 촉진하는 주요 요인은 무엇인가?
• 각기 다른 치료 영역에서 채택을 촉진하고 있는 HPAPI의 종류와 응용 분야는 무엇인가?
• 기술의 발전은 HPAPI 시장의 경쟁 구도를 어떻게 변화시키고 있는가?
• HPAPI 시장에 기여하는 주요 플레이어는 누구이며, 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 HPAPI 시장의 새로운 트렌드와 향후 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 커버리지
• 시장 정의

제3장 시장 위험과 동향 평가

• 리스크 평가
  • COVID-19 위기와 고효능 원료의약품에 대한 영향
  • 과거 위기와 비교한 COVID-19의 영향 벤치마크
  • 시장 가치에 대한 영향(금액)
  • 주요 국가에 의한 평가
  • 주요 시장 부문별 평가
  • 공급업체에 대한 행동 방침과 추천사항
• 시장에 영향을 미치는 주요 동향
• 처방과 제품 개발 동향

제4장 시장 배경

• 주요 국가별 고효능 원료의약품 시장
• 고효능 원료의약품 시장 기회 평가(금액)
• 시장 시나리오 예측
• 투자 실현 가능성 분석
• 예측요인 - 관련성과 영향
• 시장 역학

제5장 주요 성공요인

• 제조업체는 침투율이 낮지만 성장률 높은 시장에 주력
• 부문의 높은 증분 기회에 베팅
• 피어 벤치마크

제6장 세계의 고효능 원료의약품 시장 수요 분석

• 과거 시장 분석, 2019-2023년
• 현재 및 향후 시장 예측, 2024-2033년
• 전년비 성장 동향 분석

제7장 세계의 고효능 원료의약품 시장 가치 분석

• 과거 시장(금액) 분석, 2019-2023년
• 현재 및 향후 시장(금액) 예측, 2024-2033년
  • 전년비 성장 동향 분석
  • 절대적 이익 기회

제8장 세계의 고효능 원료의약품 시장 분석 : 제품 유형별

• 소개/주요 조사 결과
• 과거 시장 규모(금액·수량) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액·수량) 분석과 예측, 2024-2033년
  • 합성
  • 바이오테크놀러지
• 시장 매력 분석, 제품 유형별

제9장 세계의 고효능 원료의약품 시장 분석 : 제조업체 유형별

• 소개/주요 조사 결과
• 과거 시장 규모(금액·수량) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액·수량) 분석과 예측, 2024-2033년
  • 사내
  • 외주
• 시장 매력 분석, 제조업체 유형별

제10장 세계의 고효능 원료의약품 시장 분석 : 약물 유형별

• 소개/주요 조사 결과
• 과거 시장 규모(금액·수량) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액·수량) 분석과 예측, 2024-2033년
  • 혁신적
  • 범용
• 시장 매력 분석, 약물 유형별

제11장 세계의 고효능 원료의약품 시장 분석 : 용도별

• 소개/주요 조사 결과
• 과거 시장 규모(금액·수량) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액·수량) 분석과 예측, 2024-2033년
  • 종양학
  • 호르몬장애
  • 녹내장
  • 기타 용도
• 시장 매력 분석, 용도별

제12장 세계의 고효능 원료의약품 시장 분석 : 지역별

• 소개
• 과거 시장 규모(금액·수량) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액·수량) 분석과 예측, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동 및 아프리카(MEA)
• 시장 매력 분석, 지역별

제13장 북미의 고효능 원료의약품 시장 분석

제14장 라틴아메리카의 고효능 원료의약품 시장 분석

제15장 유럽의 고효능 원료의약품 시장 분석

제16장 아시아태평양의 고효능 원료의약품 시장 분석

제17장 중동 및 아프리카의 고효능 원료의약품 시장 분석

제18장 주요 국가의 고효능 원료의약품 시장 분석

• 미국
• 캐나다
• 멕시코
• 브라질
• 독일
• 프랑스
• 이탈리아
• 베네룩스
• 영국
• 북유럽 국가
• 중국
• 일본
• 한국
• GCC 국가
• 남아프리카공화국
• 터키

제19장 시장 구조 분석

• 기업 계층별 시장 분석
• 시장 집중
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제20장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마크
• 경쟁 상세
  • BASF SE
  • CordenPharma
  • Dr. Reddy's Laboratories Ltd.
  • CARBOGEN AMCIS AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Albany Molecular Research, Inc.
  • Sanofi SA
  • Merck &Co., Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.

제21장 사용되는 가정과 두문자어

제22장 조사 방법

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for High Potency Active Pharmaceutical Ingredients (HPAPIs). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• HPAPIs Market Size (2024E): USD 25.8 Bn
• Projected Market Value (2033F): USD 65.1 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 10.9%

HPAPIs Market - Report Scope:

High Potency Active Pharmaceutical Ingredients (HPAPIs) are critical components used in the formulation of drugs that require high levels of efficacy at low doses. These ingredients are commonly used in oncology, hormone therapy, and various other therapeutic areas. The HPAPIs market caters to pharmaceutical companies, research organizations, and contract manufacturing organizations (CMOs), offering a range of ingredients including synthetic HPAPIs, biotech HPAPIs, and others.

Market growth is driven by the increasing prevalence of chronic diseases, advancements in drug development technologies, and rising demand for targeted therapies. Enhanced efficacy, reduced side effects, and the ability to treat complex conditions are key benefits driving the adoption of HPAPIs.

Market Growth Drivers:

The global HPAPIs market is propelled by several key factors, including the growing incidence of cancer and other chronic diseases, which necessitates the development of potent and effective drugs. The shift towards targeted therapies and personalized medicine further boosts market expansion. Technological advancements, such as the development of novel drug delivery systems and continuous manufacturing processes, enhance the production and efficacy of HPAPIs, fostering market growth.

Moreover, the increasing investment in research and development by pharmaceutical companies and the rise of biologics and biosimilars contribute to the growing demand for HPAPIs. The expansion of CMOs and the outsourcing of HPAPI production to specialized facilities also play a significant role in market development.

Market Restraints:

Despite promising growth prospects, the HPAPIs market faces challenges related to stringent regulatory requirements, high production costs, and safety concerns associated with handling potent compounds. Regulatory compliance for HPAPI manufacturing involves rigorous standards to ensure worker safety and environmental protection, which can impose operational and financial burdens on manufacturers.

Additionally, the high cost of HPAPI production, including the need for specialized facilities and equipment, poses challenges for market penetration, particularly for small and medium-sized enterprises (SMEs). Addressing these regulatory and economic barriers requires collaboration between industry stakeholders and regulatory bodies to streamline approval processes and promote cost-effective manufacturing solutions.

Market Opportunities:

The HPAPIs market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of advanced manufacturing technologies, such as continuous flow processing and high containment systems, enhances production efficiency and safety.

Furthermore, the expanding application of HPAPIs beyond oncology, including in the treatment of autoimmune diseases, hormonal disorders, and cardiovascular conditions, broadens the market scope and stimulates innovation. Strategic partnerships, investment in research and development, and the introduction of novel HPAPI compounds are essential to capitalize on emerging opportunities and sustain market leadership in the dynamic HPAPI landscape.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the HPAPIs market globally?
• Which HPAPI types and applications are driving adoption across different therapeutic areas?
• How are technological advancements reshaping the competitive landscape of the HPAPIs market?
• Who are the key players contributing to the HPAPIs market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global HPAPIs market?

Competitive Intelligence and Business Strategy:

Leading players in the global HPAPIs market, including Pfizer Inc., Novartis AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced HPAPI solutions, catering to diverse therapeutic needs and clinical requirements. Collaborations with research organizations, biotechnology firms, and regulatory agencies facilitate market access and promote technology adoption.

Moreover, emphasis on clinical research, evidence-based practice, and patient safety fosters market growth and enhances patient outcomes in the rapidly evolving HPAPI landscape.

Key Companies Profiled:

• BASF SE
• CordenPharma
• Dr. Reddy's Laboratories Ltd.
• CARBOGEN AMCIS AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries, Ltd.
• Teva Pharmaceutical Industries Ltd.
• Albany Molecular Research, Inc.
• Sanofi S.A.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Cipla Inc.

Market Segments Covered in High Potency Active Pharmaceutical Ingredients Market Analysis

By Product Type

• Synthetic
• Biotech

By Manufacturer Type

• In-house
• Outsourced

By Drug Type

• Innovative
• Generic

By Application

• Oncology
• Hormonal Disorders
• Glaucoma
• Other Applications

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Summary of Statistics
• 1.3. Key Market Characteristics & Attributes
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage
• 2.2. Market Definition

3. Market Risks and Trends Assessment

• 3.1. Risk Assessment
  • 3.1.1. COVID-19 Crisis and Impact on High Potency Active Pharmaceutical Ingredients
  • 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
  • 3.1.3. Impact on Market Value (US$ Bn)
  • 3.1.4. Assessment by Key Countries
  • 3.1.5. Assessment by Key Market Segments
  • 3.1.6. Action Points and Recommendation for Suppliers
• 3.2. Key Trends Impacting the Market
• 3.3. Formulation and Product Development Trends

4. Market Background

• 4.1. High Potency Active Pharmaceutical Ingredients Market, by Key Countries
• 4.2. High Potency Active Pharmaceutical Ingredients Market Opportunity Assessment (US$ Bn)
  • 4.2.1. Total Available Market
  • 4.2.2. Serviceable Addressable Market
  • 4.2.3. Serviceable Obtainable Market
• 4.3. Market Scenario Forecast
  • 4.3.1. Demand in optimistic Scenario
  • 4.3.2. Demand in Likely Scenario
  • 4.3.3. Demand in Conservative Scenario
• 4.4. Investment Feasibility Analysis
  • 4.4.1. Investment in Established Markets
    • 4.4.1.1. In Short Term
    • 4.4.1.2. In Long Term
  • 4.4.2. Investment in Emerging Markets
    • 4.4.2.1. In Short Term
    • 4.4.2.2. In Long Term
• 4.5. Forecast Factors - Relevance & Impact
  • 4.5.1. Top Companies Historical Growth
  • 4.5.2. Growth in Automation, By Country
  • 4.5.3. High Potency Active Pharmaceutical Ingredients Adoption Rate, By Country
• 4.6. Market Dynamics
  • 4.6.1. Market Driving Factors and Impact Assessment
  • 4.6.2. Prominent Market Challenges and Impact Assessment
  • 4.6.3. High Potency Active Pharmaceutical Ingredients Market Opportunities
  • 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

• 5.1. Manufacturers' Focus on Low Penetration High Growth Markets
• 5.2. Banking on with Segments High Incremental Opportunity
• 5.3. Peer Benchmarking

6. Global High Potency Active Pharmaceutical Ingredients Market Demand Analysis 2019-2023 and Forecast, 2024-2033

• 6.1. Historical Market Analysis, 2019-2023
• 6.2. Current and Future Market Projections, 2024-2033
• 6.3. Y-o-Y Growth Trend Analysis

7. Global High Potency Active Pharmaceutical Ingredients Market Value Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033, By Product Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Product Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product Type, 2024-2033
  • 8.3.1. Synthetic
  • 8.3.2. Biotech
• 8.4. Market Attractiveness Analysis By Product Type

9. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033, By Manufacturer Type

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis By Manufacturer Type, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Manufacturer Type, 2024-2033
  • 9.3.1. In-house
  • 9.3.2. Outsourced
• 9.4. Market Attractiveness Analysis By Manufacturer Type

10. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Type

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis By Drug Type, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Type, 2024-2033
  • 10.3.1. Innovative
  • 10.3.2. Generic
• 10.4. Market Attractiveness Analysis By Drug Type

11. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033, By Application

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis By Application, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Application, 2024-2033
  • 11.3.1. Oncology
  • 11.3.2. Hormonal Disorders
  • 11.3.3. Glaucoma
  • 11.3.4. Other Applications
• 11.4. Market Attractiveness Analysis By Application

12. Global High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 12.3. Current Market Size (US$ Bn) & Analysis and Forecast By Region, 2024-2033
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. Asia Pacific
  • 12.3.5. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Pricing Analysis
• 13.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2033
  • 13.4.1. By Country
    • 13.4.1.1. U.S.
    • 13.4.1.2. Canada
    • 13.4.1.3. Rest of North America
  • 13.4.2. By Product Type
  • 13.4.3. By Manufacturer Type
  • 13.4.4. By Application
  • 13.4.5. By Drug Type
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Country
  • 13.5.2. By Product Type
  • 13.5.3. By Manufacturer Type
  • 13.5.4. By Application
  • 13.5.5. By Drug Type

14. Latin America High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2033
  • 14.4.1. By Country
    • 14.4.1.1. Brazil
    • 14.4.1.2. Mexico
    • 14.4.1.3. Rest of Latin America
  • 14.4.2. By Product Type
  • 14.4.3. By Manufacturer Type
  • 14.4.4. By Application
  • 14.4.5. By Drug Type
• 14.5. Market Attractiveness Analysis
  • 14.5.1. By Country
  • 14.5.2. By Product Type
  • 14.5.3. By Manufacturer Type
  • 14.5.4. By Application
  • 14.5.5. By Drug Type

15. Europe High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Pricing Analysis
• 15.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2033
  • 15.4.1. By Country
    • 15.4.1.1. Germany
    • 15.4.1.2. France
    • 15.4.1.3. U.K.
    • 15.4.1.4. Italy
    • 15.4.1.5. Benelux
    • 15.4.1.6. Nordic Countries
    • 15.4.1.7. Rest of Europe
  • 15.4.2. By Product Type
  • 15.4.3. By Manufacturer Type
  • 15.4.4. By Application
  • 15.4.5. By Drug Type
• 15.5. Market Attractiveness Analysis
  • 15.5.1. By Country
  • 15.5.2. By Product Type
  • 15.5.3. By Manufacturer Type
  • 15.5.4. By Application
  • 15.5.5. By Drug Type

16. Asia Pacific High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Pricing Analysis
• 16.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2033
  • 16.4.1. By Country
    • 16.4.1.1. China
    • 16.4.1.2. Japan
    • 16.4.1.3. South Korea
    • 16.4.1.4. Rest of Asia Pacific
  • 16.4.2. By Product Type
  • 16.4.3. By Manufacturer Type
  • 16.4.4. By Application
  • 16.4.5. By Drug Type
• 16.5. Market Attractiveness Analysis
  • 16.5.1. By Country
  • 16.5.2. By Product Type
  • 16.5.3. By Manufacturer Type
  • 16.5.4. By Application
  • 16.5.5. By Drug Type

17. Middle East and Africa High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Pricing Analysis
• 17.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2033
  • 17.4.1. By Country
    • 17.4.1.1. GCC Countries
    • 17.4.1.2. South Africa
    • 17.4.1.3. Turkey
    • 17.4.1.4. Rest of Middle East and Africa
  • 17.4.2. By Product Type
  • 17.4.3. By Manufacturer Type
  • 17.4.4. By Application
  • 17.4.5. By Drug Type
• 17.5. Market Attractiveness Analysis
  • 17.5.1. By Country
  • 17.5.2. By Product Type
  • 17.5.3. By Manufacturer Type
  • 17.5.4. By Application
  • 17.5.5. By Drug Type

18. Key Countries High Potency Active Pharmaceutical Ingredients Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
  • 18.1.1. Market Value Proportion Analysis, By Key Countries
  • 18.1.2. Global Vs. Country Growth Comparison
• 18.2. US High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.2.1. Value Proportion Analysis by Market Taxonomy
  • 18.2.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.2.2.1. By Product Type
    • 18.2.2.2. By Manufacturer Type
    • 18.2.2.3. By Application
    • 18.2.2.4. By Drug Type
• 18.3. Canada High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.3.1. Value Proportion Analysis by Market Taxonomy
  • 18.3.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.3.2.1. By Product Type
    • 18.3.2.2. By Manufacturer Type
    • 18.3.2.3. By Application
    • 18.3.2.4. By Drug Type
• 18.4. Mexico High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.4.1. Value Proportion Analysis by Market Taxonomy
  • 18.4.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.4.2.1. By Product Type
    • 18.4.2.2. By Manufacturer Type
    • 18.4.2.3. By Application
    • 18.4.2.4. By Drug Type
• 18.5. Brazil High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.5.1. Value Proportion Analysis by Market Taxonomy
  • 18.5.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.5.2.1. By Product Type
    • 18.5.2.2. By Manufacturer Type
    • 18.5.2.3. By Application
    • 18.5.2.4. By Drug Type
• 18.6. Germany High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.6.1. Value Proportion Analysis by Market Taxonomy
  • 18.6.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.6.2.1. By Product Type
    • 18.6.2.2. By Manufacturer Type
    • 18.6.2.3. By Application
    • 18.6.2.4. By Drug Type
• 18.7. France High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.7.1. Value Proportion Analysis by Market Taxonomy
  • 18.7.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.7.2.1. By Product Type
    • 18.7.2.2. By Manufacturer Type
    • 18.7.2.3. By Application
    • 18.7.2.4. By Drug Type
• 18.8. Italy High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.8.1. Value Proportion Analysis by Market Taxonomy
  • 18.8.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.8.2.1. By Product Type
    • 18.8.2.2. By Manufacturer Type
    • 18.8.2.3. By Application
    • 18.8.2.4. By Drug Type
• 18.9. BENELUX High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.9.1. Value Proportion Analysis by Market Taxonomy
  • 18.9.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.9.2.1. By Product Type
    • 18.9.2.2. By Manufacturer Type
    • 18.9.2.3. By Application
    • 18.9.2.4. By Drug Type
• 18.10. UK High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.10.1. Value Proportion Analysis by Market Taxonomy
  • 18.10.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.10.2.1. By Product Type
    • 18.10.2.2. By Manufacturer Type
    • 18.10.2.3. By Application
    • 18.10.2.4. By Drug Type
• 18.11. Nordic Countries High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.11.1. Value Proportion Analysis by Market Taxonomy
  • 18.11.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.11.2.1. By Product Type
    • 18.11.2.2. By Manufacturer Type
    • 18.11.2.3. By Application
    • 18.11.2.4. By Drug Type
• 18.12. China High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.12.1. Value Proportion Analysis by Market Taxonomy
  • 18.12.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.12.2.1. By Product Type
    • 18.12.2.2. By Manufacturer Type
    • 18.12.2.3. By Application
    • 18.12.2.4. By Drug Type
• 18.13. Japan High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.13.1. Value Proportion Analysis by Market Taxonomy
  • 18.13.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.13.2.1. By Product Type
    • 18.13.2.2. By Manufacturer Type
    • 18.13.2.3. By Application
    • 18.13.2.4. By Drug Type
• 18.14. South Korea High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.14.1. Value Proportion Analysis by Market Taxonomy
  • 18.14.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.14.2.1. By Product Type
    • 18.14.2.2. By Manufacturer Type
    • 18.14.2.3. By Application
    • 18.14.2.4. By Drug Type
• 18.15. GCC Countries High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.15.1. Value Proportion Analysis by Market Taxonomy
  • 18.15.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.15.2.1. By Product Type
    • 18.15.2.2. By Manufacturer Type
    • 18.15.2.3. By Application
    • 18.15.2.4. By Drug Type
• 18.16. South Africa High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.16.1. Value Proportion Analysis by Market Taxonomy
  • 18.16.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.16.2.1. By Product Type
    • 18.16.2.2. By Manufacturer Type
    • 18.16.2.3. By Application
    • 18.16.2.4. By Drug Type
• 18.17. Turkey High Potency Active Pharmaceutical Ingredients Market Analysis
  • 18.17.1. Value Proportion Analysis by Market Taxonomy
  • 18.17.2. Value Analysis and Forecast by Market Taxonomy, 2019-2033
    • 18.17.2.1. By Product Type
    • 18.17.2.2. By Manufacturer Type
    • 18.17.2.3. By Application
    • 18.17.2.4. By Drug Type
  • 18.17.3. Competition Landscape and Player Concentration in the Country

19. Market Structure Analysis

• 19.1. Market Analysis by Tier of Companies
• 19.2. Market Concentration
• 19.3. Market Share Analysis of Top Players
• 19.4. Market Presence Analysis
  • 19.4.1. By Regional footprint of Players
  • 19.4.2. Product footprint by Players

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Benchmarking
• 20.3. Competition Deep Dive
  • 20.3.1. BASF SE
    • 20.3.1.1. Overview
    • 20.3.1.2. Product Portfolio
    • 20.3.1.3. Sales Footprint
    • 20.3.1.4. Strategy Overview
  • 20.3.2. CordenPharma
    • 20.3.2.1. Overview
    • 20.3.2.2. Product Portfolio
    • 20.3.2.3. Sales Footprint
    • 20.3.2.4. Strategy Overview
  • 20.3.3. Dr. Reddy's Laboratories Ltd.
    • 20.3.3.1. Overview
    • 20.3.3.2. Product Portfolio
    • 20.3.3.3. Sales Footprint
    • 20.3.3.4. Strategy Overview
  • 20.3.4. CARBOGEN AMCIS AG
    • 20.3.4.1. Overview
    • 20.3.4.2. Product Portfolio
    • 20.3.4.3. Sales Footprint
    • 20.3.4.4. Strategy Overview
  • 20.3.5. Pfizer, Inc.
    • 20.3.5.1. Overview
    • 20.3.5.2. Product Portfolio
    • 20.3.5.3. Sales Footprint
    • 20.3.5.4. Strategy Overview
  • 20.3.6. Sun Pharmaceutical Industries, Ltd.
    • 20.3.6.1. Overview
    • 20.3.6.2. Product Portfolio
    • 20.3.6.3. Sales Footprint
    • 20.3.6.4. Strategy Overview
  • 20.3.7. Teva Pharmaceutical Industries Ltd.
    • 20.3.7.1. Overview
    • 20.3.7.2. Product Portfolio
    • 20.3.7.3. Sales Footprint
    • 20.3.7.4. Strategy Overview
  • 20.3.8. Albany Molecular Research, Inc.
    • 20.3.8.1. Overview
    • 20.3.8.2. Product Portfolio
    • 20.3.8.3. Sales Footprint
    • 20.3.8.4. Strategy Overview
  • 20.3.9. Sanofi S.A.
    • 20.3.9.1. Overview
    • 20.3.9.2. Product Portfolio
    • 20.3.9.3. Sales Footprint
    • 20.3.9.4. Strategy Overview
  • 20.3.10. Merck & Co., Inc.
    • 20.3.10.1. Overview
    • 20.3.10.2. Product Portfolio
    • 20.3.10.3. Sales Footprint
    • 20.3.10.4. Strategy Overview
  • 20.3.11. Novartis AG
    • 20.3.11.1. Overview
    • 20.3.11.2. Product Portfolio
    • 20.3.11.3. Sales Footprint
    • 20.3.11.4. Strategy Overview
  • 20.3.12. F. Hoffmann-La Roche Ltd.
    • 20.3.12.1. Overview
    • 20.3.12.2. Product Portfolio
    • 20.3.12.3. Sales Footprint
    • 20.3.12.4. Strategy Overview
  • 20.3.13. Bristol-Myers Squibb Company
    • 20.3.13.1. Overview
    • 20.3.13.2. Product Portfolio
    • 20.3.13.3. Sales Footprint
    • 20.3.13.4. Strategy Overview
  • 20.3.14. Boehringer Ingelheim International GmbH
    • 20.3.14.1. Overview
    • 20.3.14.2. Product Portfolio
    • 20.3.14.3. Sales Footprint
    • 20.3.14.4. Strategy Overview
  • 20.3.15. Cipla Inc.
    • 20.3.15.1. Overview
    • 20.3.15.2. Product Portfolio
    • 20.3.15.3. Sales Footprint
    • 20.3.15.4. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology

관련자료